131 related articles for article (PubMed ID: 27974211)
1. Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells.
Luo X; Liao R; Hanley KL; Zhu HH; Malo KN; Hernandez C; Wei X; Varki NM; Alderson N; Chu C; Li S; Fan J; Loomba R; Qiu SJ; Feng GS
Cell Rep; 2016 Dec; 17(11):2979-2993. PubMed ID: 27974211
[TBL] [Abstract][Full Text] [Related]
2. Transformation of SOX9
Chen J; Debebe A; Zeng N; Kopp J; He L; Sander M; Stiles BL
Sci Rep; 2021 Jun; 11(1):11823. PubMed ID: 34083580
[TBL] [Abstract][Full Text] [Related]
3. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
Dibra D; Gagea M; Qi Y; Chau GP; Su X; Lozano G
Cancer Res Commun; 2023 Dec; 3(12):2640-2652. PubMed ID: 38047594
[TBL] [Abstract][Full Text] [Related]
4. Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients.
Xiang D; Cheng Z; Liu H; Wang X; Han T; Sun W; Li X; Yang W; Chen C; Xia M; Liu N; Yin S; Jin G; Lee T; Dong L; Hu H; Wang H; Ding J
Hepatology; 2017 May; 65(5):1566-1580. PubMed ID: 28059452
[TBL] [Abstract][Full Text] [Related]
5. Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.
Lee J; Liao R; Wang G; Yang BH; Luo X; Varki NM; Qiu SJ; Ren B; Fu W; Feng GS
Cell Rep; 2017 Nov; 21(7):1870-1882. PubMed ID: 29141219
[TBL] [Abstract][Full Text] [Related]
6. SHP2, SOCS3 and PIAS3 Expression Patterns in Medulloblastomas: Relevance to STAT3 Activation and Resveratrol-Suppressed STAT3 Signaling.
Li C; Li H; Zhang P; Yu LJ; Huang TM; Song X; Kong QY; Dong JL; Li PN; Liu J
Nutrients; 2016 Dec; 9(1):. PubMed ID: 28035977
[TBL] [Abstract][Full Text] [Related]
7. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
[TBL] [Abstract][Full Text] [Related]
8. The Long and the Short of PTEN in the Regulation of Mitophagy.
Wang L; Lu G; Shen HM
Front Cell Dev Biol; 2020; 8():299. PubMed ID: 32478067
[TBL] [Abstract][Full Text] [Related]
9. SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.
Paccoud R; Saint-Laurent C; Piccolo E; Tajan M; Dortignac A; Pereira O; Le Gonidec S; Baba I; Gélineau A; Askia H; Branchereau M; Charpentier J; Personnaz J; Branka S; Auriau J; Deleruyelle S; Canouil M; Beton N; Salles JP; Tauber M; Weill J; Froguel P; Neel BG; Araki T; Heymes C; Burcelin R; Castan I; Valet P; Dray C; Gautier EL; Edouard T; Pradère JP; Yart A
Sci Transl Med; 2021 Apr; 13(591):. PubMed ID: 33910978
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
[TBL] [Abstract][Full Text] [Related]
11. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
Gao J; Wei B; de Assuncao TM; Liu Z; Hu X; Ibrahim S; Cooper SA; Cao S; Shah VH; Kostallari E
J Hepatol; 2020 Nov; 73(5):1144-1154. PubMed ID: 32389810
[TBL] [Abstract][Full Text] [Related]
12. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
[TBL] [Abstract][Full Text] [Related]
13. SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Chen D; Barsoumian HB; Yang L; Younes AI; Verma V; Hu Y; Menon H; Wasley M; Masropour F; Mosaffa S; Ozgen T; Klein K; Cortez MA; Welsh JW
Cancer Immunol Res; 2020 Jul; 8(7):883-894. PubMed ID: 32299915
[TBL] [Abstract][Full Text] [Related]
14. Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling.
Choi E; Kikuchi S; Gao H; Brodzik K; Nassour I; Yopp A; Singal AG; Zhu H; Yu H
Nat Commun; 2019 Apr; 10(1):1473. PubMed ID: 30931927
[TBL] [Abstract][Full Text] [Related]
15. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis.
Guo W; Liu W; Chen Z; Gu Y; Peng S; Shen L; Shen Y; Wang X; Feng GS; Sun Y; Xu Q
Nat Commun; 2017 Dec; 8(1):2168. PubMed ID: 29255148
[TBL] [Abstract][Full Text] [Related]
17. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
[TBL] [Abstract][Full Text] [Related]
18. Impact of Protein Phosphatase Expressions on the Prognosis of Hepatocellular Carcinoma Patients.
Mestareehi A; Abu-Farsakh N
ACS Omega; 2024 Mar; 9(9):10299-10331. PubMed ID: 38463290
[TBL] [Abstract][Full Text] [Related]
19. Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease.
Li YM; He HW; Zhang N
Curr Drug Targets; 2024; 25(3):171-189. PubMed ID: 38213163
[TBL] [Abstract][Full Text] [Related]
20. Risk of chronic liver disease and cirrhosis mortality among patients with digestive system cancers: a registry-based analysis.
Sun S; Shi D; Wang W
Clin Exp Med; 2023 Dec; 23(8):5355-5365. PubMed ID: 37787867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
